A Rare Case of Pulmonary Sarcomatoid Carcinoma Harboring the Gene Fusion of the Anaplastic Lymphoma Kinase With the Echinoderm Microtubule-Associated Protein-Like 4

CHEST Journal ◽  
2014 ◽  
Vol 146 (4) ◽  
pp. 637A
Author(s):  
Xiao Song ◽  
Yang Yang ◽  
Junjie Zhu ◽  
Jianfang Xu
Keyword(s):  
Anaplastic Lymphoma Kinase ◽  
Gene Fusion ◽  
Rare Case ◽  
Sarcomatoid Carcinoma ◽  
Anaplastic Lymphoma ◽  
Pulmonary Sarcomatoid Carcinoma

Anaplastic lymphoma kinase + intraoral anaplastic large cell lymphoma: A rare case report

2015 ◽  
Vol 0 (0) ◽  
pp. 0
Author(s):  
Sravani Ghattamaneni ◽  
VenkateswaraRao Guttikonda ◽  
Sivaranjani Yeluri ◽  
Jayakiran Madala
Keyword(s):  
Case Report ◽  
Anaplastic Large Cell Lymphoma ◽  
Anaplastic Lymphoma Kinase ◽  
Rare Case ◽  
Cell Lymphoma ◽  
Large Cell ◽  
Anaplastic Lymphoma ◽  
Rare Case Report ◽  
Large Cell Lymphoma

scholarly journals A RARE CASE OF PULMONARY SARCOMATOID CARCINOMA

CHEST Journal ◽  
2020 ◽  
Vol 158 (4) ◽  
pp. A1446
Author(s):  
Ayla Zubair ◽  
Chetana Pendkar ◽  
Seth Wenig ◽  
Boris Betancourt
Keyword(s):  
Rare Case ◽  
Sarcomatoid Carcinoma ◽  
Pulmonary Sarcomatoid Carcinoma

Presence of anaplastic lymphoma kinase translocation in sarcomatoid carcinoma of head and neck and treatment effect of crizotinib: A case series

Head & Neck ◽  
2015 ◽  
Vol 37 (5) ◽  
pp. E66-E69 ◽  
Author(s):  
Sung Min Kim ◽  
Moon Jin Kim ◽  
Hyun Ae Jung ◽  
Jong-Mu Sun ◽  
Yoon-La Choi ◽  
...  
Keyword(s):  
Head And Neck ◽  
Treatment Effect ◽  
Anaplastic Lymphoma Kinase ◽  
Sarcomatoid Carcinoma ◽  
Case Series ◽  
Anaplastic Lymphoma

scholarly journals Pulmonary sarcomatoid carcinoma: progress, treatment and expectations

2020 ◽  
Vol 12 ◽  
pp. 175883592095020
Author(s):  
Xin Li ◽  
Di Wu ◽  
Hongyu Liu ◽  
Jun Chen
Keyword(s):  
Cell Death ◽  
Growth Factor ◽  
Programmed Cell Death ◽  
Treatment Options ◽  
Sarcomatoid Carcinoma ◽  
Growth Factor Receptor ◽  
Anaplastic Lymphoma ◽  
Epidermal Growth ◽  
Pulmonary Sarcomatoid Carcinoma ◽  
Endothelial Growth Factor

Pulmonary sarcomatoid carcinoma (PSC) is a unique, highly invasive pulmonary malignancy with a poor prognosis, representing 0.1–0.4% of all malignant lung tumors. Because of its highly aggressive character and propensity for frequent metastasis, PSC shows low response rates to traditional treatments such as chemotherapy, radiotherapy, and neoadjuvant therapy. In recent years, considerable progress has been made in gene sequencing, targeted therapies, and immunotherapies. One of the most promising treatment approaches is the selection of mono-targeted or multi-targeted drugs according to tumor gene-mutation sites, such as epidermal growth factor receptor or vascular endothelial growth factor receptor 2 ( EGFR/VEGFR2), anaplastic lymphoma kinase ( ALK), and others. Another approach is the activation of therapeutic anti-tumor immunity via pathways including programmed cell-death protein-1/programmed cell-death ligand-1 ( PD-1/PD-L1), which has been used in individual cases. In this review, we will introduce the clinicopathologic features, molecular typing, and traditional treatments. We will also review the biological characteristics and the latest therapies for PSC. These novel therapies show promise in the management of PSC, and the outcomes of investigative trials will hopefully reveal a variety of treatment options for patients with PSC.

scholarly journals A Rare Case of Pleomorphic Carcinoma of the Lung Harboring an Anaplastic Lymphoma Kinase (ALK) Rearrangement

2015 ◽  
Vol 54 (21) ◽  
pp. 2741-2743 ◽  
Author(s):  
Takayuki Shiroyama ◽  
Ayako Tanaka ◽  
Motohiro Tamiya ◽  
Masanari Hamaguchi ◽  
Akio Osa ◽  
...  
Keyword(s):  
Anaplastic Lymphoma Kinase ◽  
Rare Case ◽  
Pleomorphic Carcinoma ◽  
Alk Rearrangement ◽  
Anaplastic Lymphoma
Sign in / Sign up

Export Citation Format

Share Document